VEGFA and central nervous system cancer: Treatment of U87 glioma cell xenografts with the anti-angiogenic inhibitor Bevacizumab (anti-vascular endothelial growth factor (VEGF) monoclonal antibody) significantly decreased the number of vessel-associated CD133+nestin+ brain cancer stem cells in mice [35].